Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies
This study supports the benefit of early and preemptive IG supplementation in reducing severe and non-severe infections in patients treated with anti-BCMA BsAbs. Prospective studies are needed to confirm these findings, assess cost-effectiveness, and define optimal IG duration and route administration.
Authors
- Clémentine Fronteau
- Chloé Antier (ORCID: https://orcid.org/0000-0001-6227-8540)
- Estelle Leroy (ORCID: https://orcid.org/0009-0003-1675-8668)
- Bénédicte Piron (ORCID: https://orcid.org/0009-0003-7960-7330)
- Viviane Dubruille
- Cyrille Touzeau (ORCID: https://orcid.org/0000-0003-0275-2575)
- Laura Rodrigo (ORCID: https://orcid.org/0000-0002-0264-8674)
- Thomas Gastinne (ORCID: https://orcid.org/0000-0003-4704-1187)
- Benoît Tessoulin (ORCID: https://orcid.org/0000-0001-7600-3329)
- Anne Lok
- Valentin Letailleur (ORCID: https://orcid.org/0000-0003-0522-6976)
- Philippe Moreau (ORCID: https://orcid.org/0000-0003-1780-8746)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1016/j.clml.2025.10.024
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00